No Data
No Data
LTR Pharma Ltd: FY24 Results Announcement
LTR Pharma Ltd: Appendix 4E and Annual Financial Report
LTR Pharma Prescribes Erectile Dysfunction Medication Under Special Access Scheme
Why Is This ASX Small Cap Ripping 37% Ahead on Tuesday?
LTR Pharma Prescribes Erectile Dysfunction Medication in Australia Under Special Access Scheme
LTR Pharma's Nasal Spray Treatment for Erectile Dysfunction Obtains Positive Early Results in Trial; Shares Surge 33%
No Data
Puntgod22 : Im thinking long term $10 is pretty reasonable.
Jason chyer OP : That was where I had set my long term bar as well. Spontan seems a winner in my eyes, just need it to continue progressing to the market